Ozempic maker Novo Nordisk’s shares plunge 18% on bleak 2026 forecast

February 4, 2026
Uncategorized

Novo Nordisk shares plunged 18% after pre-releasing a weak 2026 outlook, citing US pricing pressure on Wegovy. CEO Mike Doustdar warned of near-term headwinds despite pill launch success.

Ozempic maker Novo Nordisk’s shares plunge 18% on bleak 2026 forecast

Leave a ReplyCancel Reply

SEBI mulls overhaul of ‘fit and proper person’ framework governing market intermediaries

Here’s how much gold changed hands daily in 2025

Fractal Analytics targets 25–30% revenue growth on rising enterprise AI demand

Global Health Q3 Results: Net profit falls 33% on margin compression

Trent Q3 Results: Operating profit growth beats estimates, margin expands